business

GSK in Talks to Buy Nuvalent for More Than $9 Billion: FT

Bloomberg Markets · Jun 9, 2026, 1:25 AM · Also reported by 3 other sources

GSK Plc is in discussions to purchase cancer treatment maker Nuvalent Inc. for between $9 billion and $10 billion, the Financial Times reported, citing unidentified people familiar with the matter.

Read full story on Bloomberg Markets → More top stories

Also covered by

Financial Times GSK in talks to buy cancer biotech Nuvalent for more than $9bn Investing.com GSK in talks to buy cancer drugmaker Nuvalent for over $9 bln, FT reports Investing.com Databricks in talks to raise funds at over $165 billion, The Information reports

Aggregated and edited by the Scoop newsroom. We surface news from Bloomberg Markets alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

GSK in Talks to Buy Nuvalent for More Than $9 Billion: FT

Also covered by

More in business